Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.
Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
Sales estimated to double in 2019 and exceed EUR 50 million
Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.
GeoVax Labs, Inc. announced it has implemented a 1-for-500 reverse stock split of its common stock with a market effective date of May 2, 2019.
With revenue increase of 20 per cent in the first quarter we report all-time high net sales, first time over SEK 1.8 billion in a quarter.
The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys’s first quarter interim statement 2019 and provide an outlook for 2019.